DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Fallopian Tube
Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian
Primary Peritoneal Cancer

Interventions: Drug: ABT-767

First Posted Date: 2011-04-21

Last Posted Date: 2018-01-02

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 93

Registration Number: NCT01339650

Locations: 🇳🇱
Univ Med Ctr, St. Radboud, Nijmegen, Netherlands
🇳🇱
Univ Med Center Groningen, Groningen, Netherlands
🇳🇱
Erasmus Medisch Centrum, Rotterdam, Netherlands

Acute Pain Study Following Bunionectomy

Phase 2

Completed

Conditions: Pain

Interventions: Drug: Placebo
Drug: Hydrocodone/Acetaminophen Extended Release

First Posted Date: 2011-04-12

Last Posted Date: 2014-04-08

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 100

Registration Number: NCT01333722

Locations: 🇺🇸
Site Reference ID/Investigator# 51464, Pasadena, California, United States
🇺🇸
Site Reference ID/Investigator# 51344, Salt Lake City, Utah, United States
🇺🇸
Site Reference ID/Investigator# 51602, Austin, Texas, United States

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma

Interventions: Drug: ABT-199

First Posted Date: 2011-04-05

Last Posted Date: 2022-02-23

Lead Sponsor: AbbVie

Target Recruit Count: 222

Registration Number: NCT01328626

Locations: 🇺🇸
Dana-Farber Cancer Institute /ID# 48324, Boston, Massachusetts, United States
🇺🇸
University of Arizona Cancer Center - North Campus /ID# 52902, Tucson, Arizona, United States
🇺🇸
Ucsd /Id# 48325, La Jolla, California, United States

and more 7 locations

Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)

Completed

Conditions: Ankylosing Spondylitis

First Posted Date: 2011-04-05

Last Posted Date: 2019-04-03

Lead Sponsor: AbbVie

Target Recruit Count: 403

Registration Number: NCT01329380

Locations: 🇯🇵
Teikyo University Hospital, 板橋区, Tokyo, Japan
🇯🇵
Ozone Surgery Clinic, Aichi, Japan
🇯🇵
Asahikawa Kosei General Hosp, Asahikawa-shi, Japan

and more 190 locations

Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab

Completed

Conditions: Psoriasis

First Posted Date: 2011-04-04

Last Posted Date: 2015-07-09

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 153

Registration Number: NCT01328366

Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection

Completed

Conditions: Human Immunodeficiency Virus Infection

First Posted Date: 2011-04-04

Last Posted Date: 2014-12-22

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 236

Registration Number: NCT01328158

Locations: 🇯🇵
Site Reference ID/Investigator# 57631, Hokkaido, Japan
🇯🇵
Site Reference ID/Investigator# 57628, Kitakyushu-shi, Japan
🇯🇵
Site Reference ID/Investigator# 57634, Kyoto, Japan

and more 20 locations

Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia

Completed

Conditions: Prostate Cancer

First Posted Date: 2011-03-22

Last Posted Date: 2015-07-08

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 300

Registration Number: NCT01320735

Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment

Completed

Conditions: Psoriatic Arthritis
Psoriasis

First Posted Date: 2011-03-16

Last Posted Date: 2015-05-12

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 52

Registration Number: NCT01316224

Locations: 🇨🇴
Site Reference ID/Investigator# 48348, Cartagena, Colombia
🇨🇴
Site Reference ID/Investigator# 59342, Cali, Colombia
🇨🇴
Site Reference ID/Investigator# 53050, Cartagena, Colombia

and more 12 locations

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Phase 2

Completed

Conditions: Chronic Hepatitis C
Hepatitis C Virus (HCV) Infection

Interventions: Drug: Pegylated interferon (pegIFN)
Drug: ABT-267
Drug: Ribavirin (RBV)
Other: Placebo for ABT-267

First Posted Date: 2011-03-14

Last Posted Date: 2018-07-02

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 37

Registration Number: NCT01314261

Locations: 🇺🇸
Site Reference ID/Investigator# 52782, Kansas City, Missouri, United States
🇺🇸
Site Reference ID/Investigator# 51498, Honolulu, Hawaii, United States
🇵🇷
Site Reference ID/Investigator# 48483, San Juan, Puerto Rico

and more 8 locations

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Phase 2

Completed

Conditions: Chronic Hepatitis C Infection
Hepatitis C Virus
Hepatitis C

Interventions: Drug: ABT-450
Drug: ABT-333
Drug: ribavirin
Drug: ritonavir

First Posted Date: 2011-03-02

Last Posted Date: 2015-01-08

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 50

Registration Number: NCT01306617

Locations: 🇺🇸
Site Reference ID/Investigator# 48264, Aurora, Colorado, United States
🇺🇸
Site Reference ID/Investigator# 50424, Madison, Wisconsin, United States
🇺🇸
Site Reference ID/Investigator# 50425, Springfield, Massachusetts, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy